StudyFinder

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Enrolling by invitation
I'm interested

All
18 Years to 65 Years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
Exclusion Criteria:

• Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
• Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
• Donation of blood at any point throughout the study and for 30 days after last dose of study medication

Drug: CTP-543

Alopecia Areata

sfinder@umn.edu
Phase 2/Phase 3
NCT03898479
See this study on ClinicalTrials.gov

Back